SynthesisThe clinical respiratory journal2023
Safety outcomes of salbutamol: A systematic review and meta-analysis.
Synthesis in The clinical respiratory journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Safety outcomes of salbutamol: A systematic review and meta-analysis.The clinical respiratory journal · 2023Pooled it
- Pharmacological assessment of drugs retained in the 1Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- The effect of damp housing on psychological distress: does respiratory health matter?American journal of epidemiology · 2026Article
- Regulation of Signaling Pathways Related to Chronic Obstructive Pulmonary Disease by Chinese Medicine.Chinese journal of integrative medicine · 2026Review
- Effects of salbutamol in transient tachypnoea of the newborn: a systematic review and meta-analysis.ERJ open research · 2026Article
- Continuous versus intermittent nebulization of salbutamol in acute Severe asthma in children under 12 years of age.Pakistan journal of medical sciences · 2026Article
- Characterizing the Influence of Relative Humidity and Ethanol Content on the Dynamic Size Distributions of Aerosols Generated from a Soft Mist Inhaler.Pharmaceutical research · 2025Article
- Association of Frequent Short-Acting Beta-Agonist Inhaler Prescriptions with Acute Cardiovascular Events.Pragmatic and observational research · 2025Article
- Tips and tricks in tremor treatment.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purposeSalbutamol has been used to alleviate bronchospasm in airway disease for decades, while its potential risks have not been systematically investigated yet. The risk of any potential adverse events (AEs) in patients treated with salbutamol was assessed through systematic review and meta-analysis.
methodsA systematic search of the literature was conducted, using EMBASE, PubMed and Cochrane library, until 3 April 2023. Once the AE incidence was evaluated, randomized controlled trials (RCTs) were eligible for review. The endpoints included the incidence of total AEs, severe AEs, treatment discontinuation and specific AEs. The pooled AEs incidence was analysed via random-effects model in a single-arm meta-analysis. A subgroup study was carried out to examine whether the pooled incidence of AE differed by indications or formulations.
resultsOf the 8912 studies that were identified, 58 RCTs met the inclusion criteria and involved 12 961 participants. The analysis showed the pooled incidences of total AEs, severe AEs and treatment discontinuation in patients treated with salbutamol were 34%, 2% and 3%, respectively. Subgroup analysis indicated that premature labour users and intravenous salbutamol users were more likely associated with total AEs. The most frequently observed specific AEs were palpitations or tachycardia.
conclusionThis meta-analysis indicated that salbutamol was associated with a very common risk of palpitations or tachycardia. Clinical vigilance and research efforts are needed to optimize the safe use of salbutamol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.